Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology

Advanced search

Pharmacotherapy of insomnia in childhood

https://doi.org/10.17749/2070-4909/farmakoekonomika.2022.127

Abstract

Insomnia is the most common form of sleep disturbance in childhood. Sleep disorders and a decrease in its duration and quality lead to the development of cognitive disorders, change emotional and behavioral functions of the developing organism, and negatively affect medical and psychological aspects that require medical correction. The article provides an overview of current literature data on pharmacological approaches to insomnia therapy in childhood. The general principles of treatment and the use of various pharmacological groups of drugs are discussed. It is shown that pharmacotherapy of childhood insomnia should be carried out based on knowledge about the age characteristics of patients, efficacy, safety, analysis of pharmacodynamic and pharmacokinetic parameters of the drugs used. Drug therapy should be combined with cognitive behavioral techniques, including adherence to sleep patterns and hygiene.

About the Authors

Z. G. Tadtaeva
Saint Petersburg Pediatric Medical University
Russian Federation

Zara G. Tadtaeva – Dr. Med. Sc., Professor, Chair of Pharmacology with the Course of Clinical Pharmacology and Pharmacoeconomics. RSCI SPIN-code: 6086-0169

2 Litovskaya Str., Saint Petersburg 194100



A. N. Galustyan
Saint Petersburg Pediatric Medical University
Russian Federation

Anna N. Galustyan – MD, PhD, Associate Professor, Chief of Chair of Pharmacology with the Course of Clinical Pharmacology and Pharmacoeconomics. RSCI SPIN-code: 3303-7650

2 Litovskaya Str., Saint Petersburg 194100



V. V. Rusanovsky
Saint Petersburg Pediatric Medical University
Russian Federation

Vladimir V. Rusanovsky – Dr. Med. Sc., Professor, Chair of Pharmacology with the Course of Clinical Pharmacology and Pharmacoeconomics. RSCI SPIN-code

2 Litovskaya Str., Saint Petersburg 194100



O. A. Gromova
Federal Research Center “Informatics and Management”, Russian Academy of Sciences
Russian Federation

Olga A. Gromova – Dr. Med. Sc., Professor, Research Supervisor. WoS ResearcherID: J-4946-2017; Scopus Author ID: 7003589812; RSCI SPIN-code: 6317-9833

44 corp. 2 Vavilov Str., Moscow 119333



I. S. Sardaryan
Saint Petersburg Pediatric Medical University
Russian Federation

Ivan S. Sardaryan – MD, PhD, Associate Professor, Chair of Pharmacology with the Course of Clinical Pharmacology and Pharmacoeconomics. RSCI SPIN-code: 9522-9761

2 Litovskaya Str., Saint Petersburg 194100



M. Yu. Krivdina
Saint Petersburg Pediatric Medical University
Russian Federation

Marina Yu. Krivdina – Neurologist, Psychoneurological Department

2 Litovskaya Str., Saint Petersburg 194100



N. A. Kuritsyna
Saint Petersburg Pediatric Medical University
Russian Federation

Natalia A. Kuritsyna – MD, PhD, Associate Professor, Chair of Pharmacology with the Course of Clinical Pharmacology and Pharmacoeconomics. RSCI SPIN-code: 4361-7365

2 Litovskaya Str., Saint Petersburg 194100



References

1. Poluektov M.G. Sleep disorders in childhood: causes and modern therapy. Effektivnaya farmakoterapiya / Effective Pharmacotherapy. 2012; 1: 32–9 (in Russ.).

2. Ivanenko A., McLaughlin Crabtree V., Gozal D. Sleep and depression in children and adolescents. Sleep Med Rev. 2005; 9 (2): 115–29. https://doi.org/10.1016/j.smrv.2004.09.006.

3. Cappuccio F.P., Taggart F.M., Kandala N.B., et al. Meta-analysis of short sleep duration and obesity in children and adults. Sleep. 2008; 31 (5): 619–26. https://doi.org/10.1093/sleep/31.5.619.

4. Marcdante K., Kliegman R.M. Nelson еssentials of pediatrics. 8th ed. Elsevier; 2018.

5. Maski K., Owens J.F. Insomnia, parasomnias, and narcolepsy in children clinical features, diagnosis, and management. Lancet Neurol. 2016; 15 (11): 1170–81. https://doi.org/10.1016/S1474-4422(16)30204-6.

6. International Classification of Sleep Disorders Third Edition. Available at: https://j2vjt3dnbra3ps7ll1clb4q2-wpengine.netdna-ssl.com/wpcontent/uploads/2019/05/ICSD3-TOC.pdf (accessed 22.03.2022).

7. Kharlamov D.A., Kremenchugskaya M.R., Trifonova O.E. Polysomnography in the sleep disorders diagnostics in children. Russian Bulletin of Perinatology and Pediatrics. 2008; 53 (5): 52–8 (in Russ.).

8. Mindell J.A., Emslie G., Blumer J., et al. Pharmacologic management of insomnia in children and adolescents: consensus statement. Pediatrics. 2006; 117 (6): e1223–32. https://doi.org/10.1542/peds.2005-1693.

9. Kelmanson I.A. Pharmacotherapy of sleep disturbances in pre-school and elementary school children. S.S. Korsakov Journal of Neurology and Psychiatry. 2020; 120 (9-2): 55–61 (in Russ.). https://doi.org/10.17116/jnevro202012009255.

10. Korabelnikova E.A. Treatment and prevention of insomnia in infants and young children. Russian Journal of Psychiatry. 2012; 3: 62–70 (in Russ.).

11. Nunes M.L., Cavalcante V. Clinical evaluation and treatment of insomnia in childhood. J Pediatr (Rio J). 2005; 81 (4): 277–86 (in Portuguese).

12. Owens J.A., Mindell J.A. Pediatric insomnia. Pediatr Clin North Am. 2011; 58 (3): 555–69. https://doi.org/10.1016/j.pcl.2011.03.011.

13. Meltzer L.J. Clinical management of behavioral insomnia of childhood: treatment of bedtime problems and night wakings in young children. Behav Sleep Med. 2010; 8 (3): 172–89. https://doi.org/10.1080/15402002.2010.487464.

14. Ophof D., Slaats M.A., Boudewyns A. Sleep disorders during childhood: a practical review. Eur J Pediatr. 2018; 177 (5): 641–8. https://doi.org/10.1007/s00431-018-3116-z.

15. Kaczor M., Skalski M. Treatment of behavioral sleep problems in children and adolescents – literature review. Psychiatr Pol. 2016; 50(3): 571–84. https://doi.org/10.12740/PP/41294.

16. Morgenthaler T.I., Owens J., Alessi C., et al. Practice parameters for behavioral treatment of bedtime problems and night wakings in infants and young children. Sleep. 2006; 29 (10): 1277–81.

17. Pchelina P.V., Poluektov M.G. How to treat insomnia of early childhood. Effektivnaya farmakoterapiya / Effective Pharmacotherapy. 2016; 19: 52–9 (in Russ.).

18. Ferber R. Solve your child's sleep problems. Touchstone; 2006: 4646 pp.

19. Levin Ya.I., Kovrov G.V., Poluektov M.G., et al. Insomnia, modern diagnostic and therapeutic approaches. Мoscow: Medpraktika; 2005: 116 pp. (in Russ.).

20. Galland B., Meredith-Jones K., Gray A., et al. Criteria for nap identification in infants and young children using 24-h actigraphy and agreement with parental diary. Sleep Med. 2016; 19: 85–92. https://doi.org/10.1016/j.sleep.2015.10.013.

21. Pelayo R., Dubic M. Pediatric sleep pharmacology. Semin Pediatr Neurol. 2008; 15 (2): 79–90. https://doi.org/10.1016/j.spen.2008.03.004.

22. Owens J.F., Rosen C.L., Mindell J.A. Use of pharmacotherapy for insomnia in child psychiatry practice: a national survey. Sleep Med. 2010; 11 (7): 692–700. https://doi.org/10.1016/j.sleep.2009.11.015.

23. Relia S., Ekambaram V. Pharmacological approach to sleep disturbances in autism spectrum disorders with psychiatric comorbidities: a literature review. Med Sci (Basel). 2018; 6 (4): 95. https://doi.org/10.3390/medsci6040095.

24. Stahl S.M. Stahl’s essential psychopharmacology. Neuroscientific basis and practical application. 4 th ed. Cambridge University Press; 2013: 626 pp.

25. Walsh J.K., Krystal A.D., Amato D.A., et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep. 2007; 30 (8): 959–68. https://doi.org/10.1093/sleep/30.8.959.

26. Liskow B., Pikalov A. Zaleplon overdose associated with sleepwalking and complex behavior. J Am Acad Child Adolesc Psychiatry. 2004; 43 (8): 927–8. https://doi.org/10.1097/01.chi.0000129219.66563.aa.

27. Owens J.A., Moturi S. Pharmacologic treatment of pediatric insomnia. Child Adolesc Psychiatr Clin N Am. 2009; 18 (4): 1001–16. https://doi.org/10.1016/j.chc.2009.04.009.

28. Hatta K., Kishi Y., Wada K., et al. Preventive effects of ramelteon on delirium: a randomized placebo-controlled trial. JAMA Psychiatry. 2014; 71 (4): 397–403. https://doi.org/10.1001/jamapsychiatry.2013.3320.

29. Kawabe K., Horiuchi F., Oka Y., et al. The melatonin receptor agonist ramelteon effectively treats insomnia and behavioral symptoms in autistic disorder. Case Rep Psychiatry. 2014; 2014: 561071. https://doi.org/10.1155/2014/561071.

30. Yakhno N.N. Report on the clinical efficacy of the drug “melaxen’ by Unipharm-USA (USA) in the treatment of insomnia. Lechaschi Vrach. 1999; 10: 26–7 (in Russ.).

31. Weber J., Siddiqui M.A., Wagstaff A.J., et al. Low-dose doxepin: in the treatment of insomnia. CNS Drugs. 2010; 24 (8): 713–20. https://doi.org/10.2165/11200810-000000000-00000.

32. Kawabe K., Horiuchi F., Ochi M., et al. Suvorexant for the treatment of insomnia in adolescents. J Child Adolesc Psychopharmacol. 2017; 27 (9): 792–5. https://doi.org/10.1089/cap.2016.0206.

33. Kishi T., Nomura I., Matsuda Y., et al. Lemborexant vs suvorexant for insomnia: a systematic review and network meta-analysis. J Psychiatr Res. 2020; 128: 68–74. https://doi.org/10.1016/j.jpsychires.2020.05.025.

34. Bendz L.M., Scates A.C. Melatonin treatment for insomnia in pediatric patients with attention-deficit/hyperactivity disorder. Ann Pharmacother. 2010; 44 (1): 185–91. https://doi.org/10.1345/aph.1M365.

35. Johnson K.P., Malow B.A. Sleep in children with autism spectrum disorders. Curr Treat Options Neurol. 2008; 10 (5): 350–9. https://doi.org/10.1007/s11940-008-0038-5.

36. Bruni O., Alonso-Alconada D., Besag F., et al. Current role of melatonin in pediatric neurology: clinical recommendations. Eur J Paediatr Neurol. 2015; 19 (2): 122–33. https://doi.org/10.1016/j.ejpn.2014.12.007.

37. Andersen I.M., Kaczmarska J., McGrew S.G., et al. Melatonin for insomnia in children with autism spectrum disorders. J Child Neurol. 2008; 23 (5): 482–5. https://doi.org/10.1177/0883073807309783.

38. Dujardin S., Pijpers A., Pevernagie D. Prescription drugs used in insomnia. Sleep Med Clin. 2018; 13 (2): 169–82. https://doi.org/10.1016/j.jsmc.2018.03.001.

39. Carr R., Wasdell M.B., Hamilton D., et al. Long-term effectiveness outcome of melatonin therapy in children with treatment-resistant circadian rhythm sleep disorders. J Pineal Res. 2007; 43 (4): 351–9. https://doi.org/10.1111/j.1600-079X.2007.00485.x.

40. Lin G.J., Huang S.H., Chen S.J., et al. Modulation by melatonin of the pathogenesis of inflammatory autoimmune diseases. Int J Mol Sci. 2013; 14 (6): 11742–66. https://doi.org/10.3390/ijms140611742.

41. Bannai M., Kawai N. New therapeutic strategy for aminoacid medicine: glycine improves the quality of sleep. J Pharmacol Sci. 2012; 118 (2): 145–8. https://doi.org/10.1254/jphs.11r04fm.

42. Owens J.A., Babcock D., Blumer J., et al. The use of pharmacotherapy in the treatment of pediatric insomnia in primary care: rational approaches. A consensus meeting summary. J Clin Sleep Med. 2005; 1 (1): 49–59. https://doi.org/10.5664/jcsm.26297.

43. Meolie A.L., Rosen C., Kristo D., et al. Oral nonprescription treatment for insomnia: an evaluation of products with limited evidence. J Clin Sleep Med. 2005; 1 (2): 173–87.

44. Khachatrian L.G., Pogorelova M.S., Geppe N.A., et al. The problem of insomnia in infant/young children: issues of diagnosis and treatment. S.S. Korsakov Journal of Neurology and Psychiatry. 2019; 119 (7-2): 25–32 (in Russ.). https://doi.org/10.17116/jnevro201911907225.

45. Chutko L.S., Surushkina S.Y., Yakovenko E.A., et al. Research of kindinorm drug effectiveness in neurasthenia treatment in preschool children. Journal “Pediatria” named after G.N. Speransky. 2016; 95 (3): 140–4 (in Russ.).

46. Iakovleva E.E., Tadtaeva Z.G., Galustyan A.N., Sardaryan I.S. The problem of off-label prescriptions in the treatment of neonatal seizures. Vestnik of the Smolensk State Medical Academy. 2021; 20 (3): 43–50 (in Russ.). https://doi.org/10.37903/vsgma.2021.3.5.

47. Nguyen M., Tharani S., Rahmani M., Shapiro M. A review of the use of clonidine as a sleep aid in the child and adolescent population. Clin Pediatr (Phila). 2014; 53 (3): 211–6. https://doi.org/10.1177/0009922813502123.

48. Xue M., Brimacombe M., Chaaban J., et al. Autism spectrum disorders: concurrent clinical disorders. J Child Neurol. 2008; 23 (1): 6–13. https://doi.org/10.1177/0883073807307102.

49. Keshavan M.S., Prasad K.M., Montrose D.M., et al. Sleep quality and architecture in quetiapine, risperidone, or never-treated schizophrenia patients. J Clin Psychopharmacol. 2007; 27 (6): 703–5. https://doi.org/10.1097/jcp.0b013e31815a884d.

50. Robinson A.A., Malow B.A. Gabapentin shows promise in treating refractory insomnia in children. J Child Neurol. 2013; 28 (12): 1618–21. https://doi.org/10.1177/0883073812463069.


Review

For citations:


Tadtaeva Z.G., Galustyan A.N., Rusanovsky V.V., Gromova O.A., Sardaryan I.S., Krivdina M.Yu., Kuritsyna N.A. Pharmacotherapy of insomnia in childhood. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2022;15(2):284-293. (In Russ.) https://doi.org/10.17749/2070-4909/farmakoekonomika.2022.127

Views: 177


ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)